von Hippel-Lindau Disease (VHL)

von Hippel-Lindau Disease (VHL) is a rare genetic disorder that causes abnormal growths called tumors to develop in different parts of the body. These tumors often affect the central nervous system, eyes, kidneys, pancreas, and adrenal glands. The condition mainly impacts the body's ability to control cell growth, leading to both benign and malignant tumors. People with VHL may experience symptoms related to vision problems, high blood pressure, or neurological issues depending on the tumor location. Early detection and monitoring are important because some tumors can become cancerous or cause serious complications. The disease is inherited and affects multiple organ systems, making it a complex condition to manage.

von Hippel-Lindau Disease (VHL) is an autosomal dominant hereditary cancer syndrome caused by mutations in the VHL tumor suppressor gene on chromosome 3p25-26. The loss of VHL protein function leads to dysregulation of hypoxia-inducible factors (HIF), resulting in increased angiogenesis and tumor formation. Clinically, VHL is characterized by the development of multiple hemangioblastomas in the brain, spinal cord, and retina, as well as renal cell carcinoma, pheochromocytomas, and pancreatic cysts or neuroendocrine tumors. The disease manifests with a wide spectrum of tumors that can be benign or malignant, often presenting in young adulthood. The major clinical significance lies in the risk of life-threatening tumors and the need for lifelong surveillance. Diagnosis is supported by family history and genetic testing for VHL mutations.